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ABSTRACT   
Background 
Globally, tuberculosis is a major public health problem and especially in low-income settings 
where resources are limited for proper treatment. The disease is managed by control programs 
that follow patients throughout the treatment with outcomes routinely assessed and reported to 
promote successful TB treatment and survival of patients. However, Cameroon still records a 
large proportion of TB-related fatalities and studies have also shown a low treatment success 
rate of TB patients.  
Objectives  
We assessed treatment outcomes and factors associated with unsuccessful treatment outcomes 
on registered TB patients enrolled in the DOTS program in Laquintinie Hospital of Douala 
(LHD), Cameroon  
Methods  
A hospital-based retrospective cohort study was carried out by reviewing the TB registers of all 
TB patients enrolled in the DOTS programme at LHD from 2016-2019. Data was collected 
from all registered TB patients of all ages. Double data entry was done. For analysis we used 
crosstabulations and logistic regression to assess the determinants of unsuccessful treatment 
outcomes.  
Results  
Among the 3,321 registered cases with complete treatment outcome data, 86.9% were newly 
diagnosed. Males made up 53.9% of the new and 58.1% of the retreatment cases. 
Seroconversion was recorded in 33.8% of the new and 47.1% of the retreatment cases with 10% 
deaths among those HIV positive. New cases had 84.4% success. Retreatment cases had 74.5% 
success, 1.4% failure, 6.9% death, 6.2% lost-to-follow-up and 11.1% transferred out. For new 
cases, increased risk of unsuccessful treatment outcome was high in patients aged  ≥55years 
(aOR 1.53, 95% CI:  1.07 - 2.18), having initial smear results of (+) (aOR 1.57, 95% CI: 1.10 - 
2.22)  and  (++) (aOR 2.01, 95% CI: 1.43 - 2.83), being diagnosed and treated in the years 2017 
(aOR 1.85, 95% C.I: 1.25 – 2.73) and 2019 (aOR 2.13, 95% C.I: 1.48 – 3.06) and with double 
risk in those HIV positive (aOR 2.26, 95% CI: 1.75 - 2.92). The risk of unsuccessful treatment 
was almost double if being diagnosed and treated in the years 2017(aOR 0.53, 95%CI: 1.05 - 
6.10), and 2019 (aOR 2.93, 95% C.I: 1.34 – 6.43) for the retreatment cases. 
Conclusion and recommendation  
Treatment success of the retreatment cases (74.5%) was lower than the NTB program and WHO 
target. Proper tracing and follow-up of the “failed” and “lost-to-follow-up” retreatment cases is 
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CHAPTER ONE  
1.0 INTRODUCTION AND LITERATURE REVIEW  
1.1 Tuberculosis – causation, transmission, and site of infection  
Tuberculosis (TB) is a disease that people have for long battled with before the causative agent 
– Mycobacterium tuberculosis (Mtb) was discovered by Robert Kock in 1882 [1].   
The disease is contagious and primarily airborne, acquired by inhaling airborne droplet nuclei 
of bacilli expelled by someone with active Pulmonary Tuberculosis (PTB), for example by 
coughing, spitting, sneezing, speaking, or laughing [2, 3].  
Though the lungs is the primary site of Mtb infection (PTB), the infection can however spread 
to other secondary sites such as the pleura, lymph nodes, spine, other bones and joints, 
genitourinary tract, nervous system, abdomen through the blood stream, lymphatic system, the 
airway or by direct extension to other organs (Extra-Pulmonary Tuberculosis – ETB) [4]. 
Pulmonary tuberculosis is the most common comprising of about 80% of the total cases [2, 5] 
1.2 Tuberculosis – determinants of transmission  
People who are infected with Mtb but do not have an active TB disease cannot transmit TB. 
Children are less contagious than adults probably due to weaker cough mechanism, less sputum 
productivity and lower bacillary load [6].  Not everyone who is exposed to an infectious TB 
patient will become infected with Mtb. The probability of transmission depends on some variety 
of factors. 
• Contagiousness of the source being the greatest factor. Bacteriologically smear-
positive cases are the most infectious.  
• Virulence of the strains. Certain strains are very transmissible and more likely to cause 
active disease [5].  
• The environment where the exposure has occurred. Open air and sunlight are 
conditions that will reduce transmission while settings with no ventilation are most 
likely to lead to transmission. The proximity to a patient with active TB is also 
important.  
• Duration of the exposure. People who are close contacts such as family member, 
roommates, friends, co-workers, or other who spend multiple hours per day with an 
active TB patient are at high risk of becoming infected with the Mtb [4, 6]. 
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1.3 Tuberculosis – evolution and development in humans  
1.3.1 Tuberculosis evolution  
Upon inhalation of the infectious droplets containing the bacteria, most of the larger droplets 
stay in the upper respiratory tract (nose and throat) where infection might not develop. On the 
hand, little droplet nuclei may reach the small air sacs of the lungs (the alveoli) and in which 
case infection may occur. Thus, following exposure to the bacteria, one of the natural courses 
occurs:  
i. Latent TB infection. This is observed when the host immune response is strong and 
capable to kill the bacteria, thus preventing bacterial growth. Usually, the host has a low 
probability of experiencing TB disease in the future. 
ii. Develop into an active/a primary TB infection, which is characterised by active bacterial 
growth and multiplication, leading to the clinical stage of the disease, for example, 
military TB and TB meningitis 
iii. Post-primary TB. A clinical stage where the dormant bacilli get a chance to multiply 
and grow, a process known as reactivation [3]. 
1.3.2 Tuberculosis development in humans  
There are two main stages in which TB develops in humans: TB infection and TB disease.  In 
the first stage, an infectious case of TB spreads the bacteria to another person who is exposed 
to and then becomes infected. Then second stage, TB occurs when the infected individual 
develops the disease [5].  
1.3.2.1 Primary infection 
Following transmission on the bacteria into the body, it multiplies slowly mainly in the terminal 
alveoli of the lungs and in the lymph nodes. After one to two months, because of cellular 
immunity, the primary focus (defined as “small area of granulomatous inflation in the alveoli, 
which is not detectable on chest x-ray unless calcifies or grows substantially” [7]) will be 
contained and encapsulated with a central zone of parenchymal necrosis. At this moment, 
specific TB immunity appears and positive skin reaction to tuberculin is observed. This stage 
is usually asymptomatic though hypersensitivity reaction may occur in rare cases [7, 8].  
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1.3.2.2 Active TB disease  
Bacilli from the primary infectious focus or from a near-by lymph node can be transported and 
disseminated throughout the body via the lymph system or bloodstream before immunity is 
established. This may result to secondary foci containing bacilli in other areas of the body 
particularly in the lungs, lymph nodes, serous membranes, meninges, bones and kidneys. 
However, when immune response is mounted, most of these foci are resolved but a number of 
bacilli may remain latent in the secondary foci for months or even years [9].  
A variety of factors can reduce immunity and thus lead to reactivation of the bacilli and their 
proliferation in one or more of these foci. Active TB disease then results from reactivation or 
progression of the primary or secondary foci.  Half of the cases of active TB appear in the year 
following infection though active TB cases may occur after months or even after years without 
clinical signs following primary infection [7, 8].   
1.4 Tuberculosis - risk factors for developing active TB disease 
The risk of developing to active TB disease depends on several factors including: factors that 
affect or weaken the immune systems, factors that damage the lungs, the intensity and duration 
of exposure [9].   
1.4.1 Factors that affect the host immune defences 
Infection with human immunodeficiency virus (HIV) is one of the main factors that greatly 
affects the immune system, specifically the white blood cells called CD4 cells. People living 
with the virus develops the acquired immunodeficiency syndrome (AIDS) which makes them 
disease prone including developing TB disease [5, 10]. The immune system prevents the 
development of TB following tuberculous infection. However, when this protection provided 
by the immunes systems is reduced by HIV infection, the microbe introduced from the new 
infection or that which was dormant in the body of someone previously infected can begin to 
multiply and cause TB [5]. The risk of coming down with active TB in someone with HIV 
infection is multiplied 20 – 40 times [11].  
Other factors that weaken the host immune defences include diabetes mellitus (risk multiplied 
by 3-5 times) [9] and also associated with increased risk of developing primary multi drug 
resistant (MDR) TB [12]. Moreover, malnutrition; prolonged therapy with corticosteroids (such 
as prednisolone); other immunosuppressive therapies; certain types of cancer such as 
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leukaemia, Hodgkin’s lymphoma, cancer of the head and neck; several kidney diseases; 
alcoholism; substance abuse; pregnancy also weaken the immune system and increase the risk 
of developing TB [11]. Furthermore, young children and persons over sixty years have greater 
risk due to immune system not fully developed for the former and comorbidities for the later 
[13].  
1.4.2 Factors that enhance damage the lungs  
Chronic alcoholism has been associated with acute respiratory distress syndrome (ARDS) and 
lung injury [14, 15].  Also, studies show risk of developing active TB is greatly increased in 
people who drink daily more than 40g of alcohol or have alcohol disorder [16], and heavy 
alcohol consumption /alcohol use disorder (AUD) being a risk factor for TB incidence and re-
infection [17]. Consistence and subsistence evidence from several reviews show strong 
association between lung damage, lung cancer and smoking tobacco, waterpipe tobacco 
smoking, marijuana smoking [18-20]; TB and tobacco smoking, including passive smoking and 
indoor pollution exposures [21, 22] and in some studies causal association between smoking 
and TB disease [23]. “Dose-response” analysis in systematic reviews show strong association 
between Silicosis with lung cancer [24] and even low doses of silica increase the risk of 
developing TB [25]. 
1.4.3 Intensity of exposure 
This refers to the number or quantity of inhaled bacilli [26]. Factors such as the contagiousness 
of the source, the environmental and proximity in which the exposure took place, duration of 
the exposure and residents of high-risk areas do affect the risk of developing active TB. [9, 11]. 
Studies in Brazil show increased risk of TB infection with intensity of exposure to patients with 
pulmonary TB [27]; case control study showed increase exposure may serve as a very good 
indicator of increased risk of progression to TB disease in Canada [28]; and exposure to PTB 
cases indicated strong risk of TB transmission to other inmates in Aba federal prison, Nigeria 




1.5 TB diagnosis and treatment 
TB diagnosis can be done using sputum smear microscopy (developed more than 100 years 
ago), rapid molecular tests (first endorsed by WHO in 2010) and culture-based 
methods [2]. The culture-based takes up to 12 weeks to provide results but remain the reference 
standard. TB that is resistant to first line and second-line anti-TB drugs can be detected using 
rapid tests, culture methods and sequencing technologies.   
The WHO recommends essential formulations of anti-TB drugs and fixed-dose combinations 
for the treatment of tuberculosis comprising of two main phases: intensive and continuation 
phase. The intensive phase consist of four (4) anti-TB drugs for two month with the main 
purpose of killing the bacteria rapidly, render the patient less infectious, disease control, prevent 
emergence of drug resistance and the continuation phase to sterilize by killing dormant and 
semi-dormant bacilli and prevent relapse of TB [30]. Essential anti-TB drugs are isoniazid (H, 
INH), rifampicin (R, RMP), ethambutol (E), pyrazinamide (Z) and Streptomycin (S) [30]. 
WHO recommends standard regimen and dosing frequency for new TB patients for intensive 
phase (2 months of HRZE) and for the continuation phase (4 months of HR) and whereas for 
countries with high levels of isoniazid resistance in new TB patients, and where isoniazid drug 
susceptibility testing in new patients is not done (or results are unavailable) before the 
continuation phase begins the recommendations are: intensive phase (2 months of HRZE) and 
for the continuation phase (4 months of HR) [5, 30]. 
In Cameroon, TB treatment is provided only by the National Tuberculosis Control Program 
(NTCP) at no cost with the combinations in line with the WHO recommendations [31].  The 
patients to be treated as tuberculosis cases are determined based on: 
▪ The bacteriological status 
▪ The localization of the disease – pulmonary or extra-pulmonary 
▪ Past treatment history of the patient – never treated or previously treated for TB [32]. 
These patients are thus classified as new or retreatment cases.  
New cases 
Patients who have never been treated before or have been treated for less than one month with 
anti-TB drugs. They include: 
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▪ Pulmonary TB confirmed bacteriologically or my microscopy, molecular test (Xpert or 
TB-LAMP) and or culture (PTB+) 
▪ Bacteriologically unconfirmed pulmonary TB (PTB-) 
▪ Extra-pulmonary TB (EPTB) 
Retreatment cases 
These patients fall under three main treatment groups: relapse, treatment failures, return after 
default and should be rifampicin sensitive. 
Relapses: patients who previously had received anti-TB treatment for active TB 
(bacteriologically confirmed or not) and were declared “cured” or “treatment completed” but 
later developed bacteriologically confirmed PTB. 
Treatment failures: PTB patients on treatment who are still sputum smear positive 5 months 
or more after starting anti-TB treatment.  
Return after default: new TB patients who had been in treatment for 1 month or longer and 
have returned with symptoms of PTB and positive sputum smear after having interrupted 
treatment for 2 months or more [32].  
A new regimen was to put in place by 2020 in which Streptomycin was removed from the 
regimen for retreatment adult cases [32]. Treatment regimen up to the years 2019 and from 
2020 are shown in the table 1.1 below and table 1.2 in the next page.  
Table 1.1: Drug regimen for the treatment of new and retreatment TB cases in 
Cameroon before 2019  
 Intensive phase treatment Continuation phase  
New cases  2-months of rifampicin (R, RMP), 
isoniazid (H, INH), ethambutol (E) and 
pyrazinamide (Z) (2RHEZ) 




2 months of RHEZ and streptomycin (S)  
(2RHEZS) 
1 month of RHEZ and  
5 months of RHE 
(1RHEZ/5RHE) 
Source: TB technical guide for health personnel in Cameroon, 2020 (pg. 145) 
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Table 1.2: Drug regimen for the treatment of new and retreatment TB cases in 
Cameroon from 2020 
 Intensive phase treatment Continuation phase  
New cases  2-months of rifampicin (R, RMP), 
isoniazid (H, INH), ethambutol (E) 
and pyrazinamide (Z) (2RHEZ) 




3 months of rifampicin (R, RMP), 
isoniazid (H, INH), ethambutol (E) 
and pyrazinamide (Z) (3RHEZ)  
(“Under very strict DOT observation 
on outpatient or in the hospital in 
case of severe clinical status of 
patient or if difficult to supervise 
patient on outpatient basis”) 
3 months of rifampicin (R, RMP), 
isoniazid (H, INH), ethambutol (E) 
and pyrazinamide (Z) (3RHEZ) 
Source: TB technical guide for health personnel in Cameroon, 2020 (pgs. 50, 145) 
1.6 The Directly Observed Treatment (DOTS) program  
According to WHO, the best curative method and most cost-effective way to stop the spread of 
TB in communities with high incidence is known as DOTS. The Directly Observed Treatment 
Short Course (DOTS, also known as TB-DOTS) is the name given to the TB control strategy 
recommended by the WHO [33]. 
The five main components of the DOTS program include:  
- Government commitment (including political will at all levels, and establishment of a 
centralized and prioritized system of TB monitoring, recording, and training). 
- Case detection by sputum smear microscopy. 
- Standardized treatment regimen directly of six to nine months observed by a healthcare 
worker or community health worker for at least the first two months. 
- Drug supply. 




Dr Karel Styblo of the International Union Against TB and Lung Disease (IUATLD) developed 
the technical strategy in 1970s which was then taken by the WHO and made into a Global 
strategy and dubbed DOTS [34].  Later the strategy is named STOP TB strategy and End TB 
strategy and all of them still include the 5 DOTS main components. Almost all countries had 
adopted the strategy, and there was considerable progress towards global targets established for 
2005 [35]. However, the growing HIV epidemic represents a great challenge for the National 
Tuberculosis Programs (NTPs), which are seeing an increase in HIV infection among TB cases 
and the appearance of new TB cases among persons infected with HIV. This is compromising 
health system performance and NTP efficiency due to increased TB incidence, case-fatality, 
treatment abandonment, and challenges for the comprehensive treatment of both diseases [5]. 
It is important to notice that the direct observation (DOT) is just one of the several components 
of the “DOTS” strategy, this is sometimes comprehended.  
1.7 Factors affecting TB treatment outcomes  
The goal of TB treatment is to ensure relapse-free cure while presenting the emergency of drug 
resistance. Thus, sterilization, elimination of the bacilli from the sputum and not only about 
healing of lesions could be used to judge the effect of treatment. Mindful of the fact that Mtb is 
a slow-growing aerobic organisms and can remain dormant for a prolonged time, prolonged 
treatment with multiple drugs is needed to ensure cure without relapse and also prevent the 
emergence of resistance [36]. Bacteriology, environmental (anatomical and biochemical) and 
pharmacological factors play a major role of determining the treatment effect [37].  
1.7.1 Bacteriological factors  
1.7.1.1 The numerical factor  
The number of tubercle bacilli varies widely with the type of lesion present. Data from lung 
specimen resected from untreated patients show that the number of bacilli in a medium-sized 
cavity communicating with the bronchi is about 100 million whereas the number in an 
encapsulated nodular lesion of the same size with no bronchial communication be as low as one 
hundred. The larger the bacterial population, the higher the probability of resistant mutant 
strains that might be present even before treatment [36].  
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1.7.1.2 The metabolic factor  
Medications do kill organisms that metabolize actively and continuously, but in each bacterial 
population there are bacilli with low metabolic rate. This slow metabolic rate might be enhanced 
by low pH or some bacteria might just be dormant. The organisms are called “persisters” and 
even survive in the presence of isoniazid and streptomycin. However, rifampicin or 
pyrazinamide may attack and effectively kill these bacilli under certain conditions. This 
explains why to some extent why not all bacilli are killed during treatment, and why drug-
susceptible bacilli are coughed out for some time even after treatment [36]. 
1.7.2 Environmental factors  
1.7.2.1 The anatomical factors  
The type of tissue harbouring tubercle bacilli may affect drug action because not all drugs are 
able to penetrate all tissues and cells or permeate biological membranes, including the normal 
blood-brain barrier. Isoniazid, rifampicin, and pyrazinamide readily cross biological 
membranes, whereas streptomycin fails to enter many cells and in much less effective against 
intracellular than extracellular bacilli [36].   
1.7.2.2 Biochemical factors  
Partial oxygen pressure, environmental pH are important biochemical factors that influence the 
antimicrobial effect of a drug [38].  In a cavity wall, at neutral pH, all the bactericidal 
antituberculosis drugs are highly effective. However, streptomycin is at most active in a slightly 
alkaline environment, whereas pyrazinamide acts largely in an acidic medium such as that 
found inside cells [39, 40]. With respect to factors relevance to dormancy of bacilli, it is 
stipulated that dormant organisms survive within the cells or in necrotic areas of old 
encapsulated lesions that do not communicate with the bronchus.  
The partial oxygen is an important factor, shown by the small number of bacilli found in closed 
extrapulmonary lesions [26].    
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1.7.3 Pharmacological factors  
1.7.3.1 Dosage 
The dosage of drugs should be large enough to produce inhibitory concentration at the site 
where bacilli are found, but not necessary to keep the concentration constant [26].   
1.7.3.2 Combination of drugs 
Regimens should contain a combination of three or more drugs, particularly in the initial phase 
of TB treatment. In the early days of treatment, patients were given one drug; if that failed, 
further drugs were successively substituted or added, one at a time with the results that these 
people eventually became chronic patients with organisms resistant to all the drugs they had 
received. Thus, treatment of tuberculosis disease should never be attempted with a single drug, 
nor should a single dug be added to a failing regimen [5, 36].   
1.7.3.3 The “lag period” factor  
From experiment, when the tubercle bacilli are exposed to a drug for a short time (6-24 hours) 
and after careful removal of the drugs, are transferred to a drug-free medium, the surviving 
bacilli start to grow again after an interval of several days. This interval called the “lag period” 
varies with the type of concentration of the drug and with the length of exposure [36].   
1.7.4 HIV/AIDS 
TB is the most common opportunistic disease in PLHIV in countries with high prevalence of 
the two diseases. The immunological effect of HIV is manifested mainly on cell-mediated 
immunity, the part of the immune system vital in the response against M. tuberculosis. Thus, 
the immune deficiency caused by HIV infections greatly reduces the capacity of the host to 
contain TB infections, prevent a new infection or re-infection by M. tuberculosis. HIV and TB 
have a bidirectional interaction as M. tuberculosis increases the replication of HIV in vitro and 
HIV speeds up the evolution of TB infection into active TB disease [32].  
Thus, patients infected with HIV usually have a response to treatment like those who are not 
infected with HIV, with a few exceptions. However, they are more likely to die during the 
treatment, usually from causes other than TB. Also, they may be more likely to experience toxic 
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reactions to drugs than those who are not HIV-infected, increase pill burden with the possible 
impact on adherence, TB immune reconstitution inflammatory syndrome [5, 32, 36].   
1.8 Factors that influence adherence to TB treatment 
Adherence to treatment is needed to attain the maximum benefits from the drugs. However, 
factors ranging from the level of the patient, treatment-related and the therapeutic environment 
can influence the adherence treatment. It is possible to control the treatment and therapeutic-
related factors but not always possible to control those related to the patient. These factors 
influence treatment adherence and abandonment, which affects the treatment out comes [32, 
41, 42].  
1.8.1 Patient-related factors 
This includes: 
▪ Socioeconomic factors like having a job, being stigmatized, being marginalized, family 
support [43]. 
▪ Psychological factors for example having the feeling discouragement or not. 
▪ Knowledge and perception of the disease. For example, patient might continue 
treatment if there’s improvement or abandoning if no improvement. Also, not taking 
treatment id disease is attributed to supernatural causes [44]. 
1.8.2 Factors related to the treatment 
This includes: 
▪ The simplicity of treatment such as fixed dose combinations simplifies the treatment by 
reducing the number of tablets.  
▪ Adverse effects of the treatment  
▪ Direct observation of treatment of the patient by health support staff [26]    
1.8.3 Factors related to the therapeutic environment  
This includes: 
▪ Waiting time at the health facilities, the way patients are welcomed at the clinics, patient 
accommodation for hospitalised patients. 
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▪ The closeness of drug distribution centres to the patients  
▪ Relationship between the health workers and the patients. A good patient health worker 
relationship will make patient more likely to follow instruction to take medication and 
vice versa.  
▪ The co-management of HIV infection and TB requires coordination between the TB and 
HIV/AIDS programs at all levels [45].  
▪ Subsidized or free health care (consultations, laboratory test, drugs, etc) reduces the 
number of dropouts.  
▪ Drug availability, management, and supply. The drug supply process should be rigorous 
to avoid shortages, which can lead to treatment interruptions and of coz impact 
adherence and treatment outcome negatively. 
The coordination for other diseases like diabetes, HIV and hypertension in the same health 
facility will decrease the burden on the patients [32, 42, 45].   
1.9 Global and national burden of tuberculosis  
Tuberculosis (TB) is still a major cause of ill health - among the ten top causes of death 
worldwide. It is the leading cause of mortality among PLW HIV and deaths related to 
antimicrobial resistance [2].  
In 2019, WHO estimated 10 million people globally fell ill to TB, 5.6 million were men, 3.2 
million were women and 1.2 million children. There were 1.4 million TB deaths among HIV-
negative people and 208,000 TB deaths among HIV-positive people [46]. 
According to the World Health Organization (WHO) regions 44% of TB cases were reported 
in South-East Asia, Africa (25%), the Western Pacific (18%), the Eastern Mediterranean 
(8.2%), the Americas (2.9%) and Europe (2.5%) and with eight countries accounting for 66% 
of the new cases: India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and 
South Africa [46]. 
Drug-resistant TB accounted for about half a million new cases of rifampicin-resistant TB (RR 
TB) - of which 78% had Multidrug-Resistant Tuberculosis (MDR-TB). India (27%), China 
(14%) and the Russian Federation (8%) had the largest share of the global burden. Globally, 
3.3% of new TB cases and 17.7% of previously treated cases had MDR-TB and RR-TB, with 
the highest proportions (>50% in previously treated cases) in countries of the former Soviet 
Union. The global treatment success rate for MDR/RR-TB stands at 57% [46].  
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In 2019, the estimated Disability Adjusted Life Years (DALYs) lost due to tuberculosis stood 
at the global level, for Sub-Saharan Africa and for Cameroon at 47,030,118, 17,547,389 and 
291,908 respectively [47].  
Cameroon is ranked in the top 30 countries with high TB/HIV burden countries in the world 
and in the top 20 countries with the highest estimated number of incident TB cases among PLW 
HIV in 2019 [48].  In 2019, the estimated rates per 100,000 populations were: TB incidence 
179 (116–255), HIV-positive TB incidence 48 (31–69) and MDR/RR-TB incidence 3.6 (1.7–
6.9). The HIV-negative TB mortality and HIV-positive TB mortality per 100,000 stood at 29 
(17–43) and 19 (12–28) respectively [48]. 
1.10 The global plan to End TB 2016-2030 
In the years 2014 and 2015, all Member States of the World Health Organization (WHO) and 
the United Nations (UN) committed to ending the TB epidemic. They unanimously endorsed 
the WHO’s End TB Strategy at the World Health Assembly in May 2014, and by adopting the 
UN Sustainable Development Goals (SDGs) in September 2015. The SDGs were set up in 2015 
by the United Nations General Assembly and are intended to be achieved by 2030 and SDG 
Target 3.3 includes ending the TB epidemic by 2030 [35].   
The vision of this strategy is to ensure a world free of TB - ensuring zero deaths, disease and 
suffering due to tuberculosis and the goal is to end the global TB epidemic [35]. 
The global plan to End TB has milestones for 2025 and targets for 2035. 
The milestones for 2025 include: 
- 75% reduction in tuberculosis deaths - compared with 2015. 
- 50% reduction in tuberculosis incidence rate (less than 55 tuberculosis cases per 
100,000 population) – compared with 2015. 
- No affected families facing catastrophic costs due to TB.  
The targets for 2035 include: 
- 95% reduction in tuberculosis deaths (compared with 2015). 




- No affected families facing catastrophic costs due to tuberculosis [2, 35]. 
1.11 The National TB Control Program (NTCP) of Cameroon  
The mission of the NTCP is to eliminate TB as a public health problem in Cameroon. The 
NTCP is organized at all levels of the health pyramid: the central level (the Ministry of Public 
Health, MoPH), the regional Level and the operational level [32].  
Goal  
The goal is to reduce the incidence of TB from 186 cases per 100,000 inhabitants to 130 cases 
per 100,000 by 2024 and to reduce TB deaths from 54 per 100,000 to 32 per 100,000 in the 
same period.  
The specific objectives are: 
▪ Intensify TB case finding especially among vulnerable and or at-risk population and 
increase the treatment success rate to 90% by 2024. 
▪ Test 95% of TB patients for HIV and put 100% of coinfected cases on antiretroviral 
therapy by 2024. 
▪ Increase to 95% the screening for HIV of TB patients and increase to 100% the treatment 
by ARVs of coinfected patients by 2024. 
▪ Increase to 85% screening for multidrug resistant TB in the target populations and to 
100% linkage to treatment for those patients detected with MDR-TB by 2024. 
▪ Protect people living with HIV with isoniazid preventive therapy in collaboration with 
the National AIDS Control Committee (NACC) 
▪ Improve on the management practices of the programme at all levels of the health 
pyramid [32]. 
The strategies for the implementation of the NTCP are: 
- Screening and diagnosing of TB. 
- Correct treatment of patients. 
- Prevention of disease. 
- Community participation. 
- Training of health personnel. 
- Epidemiological surveillance. 
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- Systematic screening for and management of HIV in TB patients and TB in HIV 
infected patients. 
- Early detection and management of MDR-TB [32].  
The Sustainable Development Goal (SDG) number 3 states: “Ensure healthy lives and promote 
well-being for all ages”. Target 3.3 by 2030, end the epidemics of AIDS, tuberculosis, malaria 
and neglected tropical diseases and combat hepatitis, water-borne diseases, and other 
communicable diseases [49].  
The National TB Control Program of Cameroon (NTCP) aims to achieve TB treatment success 
rate of ≥87% by 2020 [50]. This target is in line with the End TB strategy which recommends 
≥90% TB treatment success rate in 2025 latest [2]. 
1.12 TB and the Coronavirus disease 2019 (COVID-19) 
Coronavirus disease 2019 (COVID-19 for short) is the name of the infectious disease caused 
by the newly discovered coronavirus (SARS-CoV-2 coronavirus) and declared a pandemic by 
the director of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus on 
March 11, 2020. It spreads primarily through droplets of saliva or discharge from the nose when 
an infected persons coughs or sneezes [51].    
Some people infected with the virus have no symptoms. However, common symptoms include 
fever, body ache, dry cough, fatigue, chills, headache, sore throat, loss of appetite and loss of 
smell. In others, severe symptoms like high fever, severe cough, and shortness of breath could 
be present. The number of infected people changes very rapidly [51]. 
Recent progress in reducing the global burden of the TB disease is being threatened by the 
COVID -19 pandemic [46]. Based on modelling analysis, predictions have been made on the 
annual number of TB deaths to increase globally when compared to the era before Covid 19 
due to decrease in detection, reporting and treating of TB cases, as a result of lock down, 
disruption of health services and people do not go to the health facilities [46]. Studies done by 
the Stop TB program and partners estimate between the years 2020 and 2025: 1.4 million TB 
deaths if long durations of lock down are implemented with delayed restoration of services [46, 
52]. 
Moreover, key determinants of TB incidence (GDP per capita and under nutrition) have also 
been predicted to worsen because of the economic impact of the pandemic. Modelling predicts 
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unemployment/lost income, and increase number of people with TB./households facing 
catastrophic cost could cause a yearly increment of more than one million people developing 
TB between the years 2020-2025 [46].  
As the Covid-19 pandemic continues, TB endemic countries reported reallocation of TB health 
care workers and other material resources from TB programs to combat Covid-19, as well as 
significant drop in TB notification implying that a huge number of people with TB are going 
on reported, untreated and are probably transmitting the infection. Global TB experts fear there 
could be is a great risk for a surge in TB cases and mortality after the Covid-19 pandemic and 
argue that if global responses to TB are not improved upon, catastrophic clinical and economic 
implications could be recorded in TB and could reverse the gains achieved in the TB control 





1.13 Statement of the problem 
TB remains a major public health problem globally and especially in resource-poor settings [2]. 
In Cameroon, it is reported that TB infection is among the ten top causes of death [47]. 
Moreover, Cameroon is ranked in the top 30 countries with high TB/HIV burden countries in 
the world and in the top 20 countries with the highest estimated number of incident TB cases 
among PLW HIV in 2019 [2, 54, 55].  A third of all TB cases in Cameroon were recorded in 
the two major cities of Douala and Yaoundé. Previous study done in 2013 to describe the 
clinical characteristics and outcomes of tuberculosis in the Laquintinie Hospital of Douala, 
Cameroon (HLD) showed a low treatment success rate of TB patients which might have 
accounted for fatalities [31].  Therefore, we wanted to assess any changes in treatment outcomes 
and to identify factors associated with unfavourable outcomes among registered TB patients in 
the Laquintinie Hospital of Douala, Cameroon; this may help the TB control programme how 





1.14 Objective  
1.14.1 Main objective 
To study the treatment outcome of registered TB patients enrolled in the DOTS programme 
from 2016 to 2019 in Laquintinie Hospital of Douala, Cameroon  
1.14.2 Specific objectives 
1) To describe the treatment outcomes of registered TB patients.  





2.0 RESEARCH METHODOLODY 
2.1 Study design, study site, and period  
2.1.1 Study design  
A hospital based retrospective cohort study aimed at assessing the treatment outcomes of 
registered TB patients enrolled in the DOTS program in Laquintinie Hospital of Douala (LHD), 
in the Littoral region of Cameroon from 2016 to 2019. The data was collected from December 
01, 2020 to January 30, 2021. 
2.1.2 Study site and period  
LHD is found in the heart of Akwa, Deido health district of Douala, Littoral Region of 
Cameroon. It extends over nine hectares, and it is a reference hospital of second category [56]. 
The TB clinic of the LHD is the biggest in Douala and the second largest in Cameroon after the 
Yaounde Jamot Hospital [31].  
Douala is the largest city and the economic capital of Cameroon. It is the headquarters of the 
Cameroon’s Littoral Region and the home to Central Africa’s largest port. As of 2018, the 
estimated population stood at 2,768,400 [57]. The city sits on the estuary of the Wouri River 
and has a tropical climate with warm and humid conditions with an average annual temperature 
of 27.0 °C (80.6 °F) and an average humidity of 83% [58].   
After the end of the millennium development goals in 2015, the Cameroon National TB Control 
Program had as national baseline success rate of 82%. With the commence of the SDGs from 
2016, projections were made for estimated treatment success rates from 2016-2020. Mbatchou 
et al., 2013 reported treatment success rate of 75.2% at the HLD and made recommendations 
[31], however a follow-up study is yet to be done.  Thus, looking at the treatment outcomes 
within this study period from 2016 – 2019 which happens to be the first quarter of the SDGs, 
from a major treatment centre like the LHD which help to address issues to at the hospital and 





2.2 Source population 
All patients registered for TB treatment at LHD from January 2016 – December 2019.  
2.3 Study participants  
All registered TB patients registered at the LHD and enrolled in the DOTS programs and had 
treatment outcome at from January 2016 – December 2019.  
2.4 Inclusion and exclusion criteria 
2.4.1 Inclusion criteria 
i. Registered TB patients in the DOTS program at the LHD of all ages  
2.4.2 Exclusion criteria 
i. Patients who have more than one final treatment outcomes.  
There are six major final treatment outcomes which are mutually exclusive: cured/ 
completed treatment/ lost to follow-up/ failed/ died/ transferred out. Thus, if a patient 
had two final treatment outcomes for example cured and at the same time lost to follow 
up, then patient was excluded from the study.  
ii. Patients with incomplete patient data  
2.5 Data collection 
The TB registers in the TB clinic was used get relevant information for the demographic 
information and treatment outcome of patients. The outcome / dependent variable is the 
treatment outcome which can take only one of six values: cured/ completed treatment/ lost to 
follow-up/ failed/ died/ transferred out to other health facilities.  
The independent/exposure variables are demographic characteristics of patients including sex, 
age, date of registration; clinical characteristics of patients including type of TB 
(pulmonary/extrapulmonary), type of patient (new or retreatment), HIV status, antiretroviral 




2.6 Data entry, validation, analysis, and presentation  
Data was entered in a template created in Epidata. Double data entry was done to ensure data 
quality assurance and validation.  
Statistical Package for Social Sciences (SPSS) version 26 was used for data analysis and the 
results are presented in tables and figures in terms of group bases of the patients (new cases and 
retreatment cases).  
Crude (bivariate) and adjusted (multivariate) logistic regression analysis was performed, and 
we regarded odds ratios an approximation for risk.    
For objective 1, the results described using crosstabulation of the treatment outcomes (cured, 
completed, died, lost-to-follow-up, transferred out) by age, gender, HIV status, ART status, 
type of TB, type of patient, sputum smear result (Neg/+/++/+++).  
For objective 2, the determinants of unsuccessful treatment outcomes were obtained from 
logistic regression.  
 
2.7 Operational definition of key terms  
TB infection: Infection with the bacilli of Mycobacterium tuberculosis. 
Active TB disease: Presence of signs and symptoms of TB disease in an individual who is 
infected with the bacilli of Mycobacterium tuberculosis. 
Case of tuberculosis: A definite case of pulmonary TB with one or more initial sputum 
smear positive for acid-fast bacilli or one in which a health worker has diagnosed TB and has 
decided to treat the patient with a full course of DOTs. 
New case: without or with less than 1 month of previous treatment. 
HIV infection: Infection with the Human Immune-deficiency Virus (HIV) that is confirmed 
by first line and second-line serologic tests. 
HIV/TB co-infection: The presence of both HIV and TB infection in an individual patient. 




Cured: An initially sputum smear-positive patient who is sputum smear negative at or one 
month prior to, the completion of TB treatment and on at least one previous occasion (usually 
at the end of the second or fifth month). 
Treatment completed: A patient who completed anti-TB treatment without evidence of 
failure but for whom sputum smear or culture results are not available in the last month of 
treatment and on at least one previous occasion. 
Treatment failure: A patient whose sputum smear or culture is positive at the fifth month of 
treatment or later during the course of treatment. Also included in this definition are patients 
found to harbour a multi-drug resistant strain at any point of time during the treatment, 
whether they are smear-negative or positive. 
Lost to follow-up: (formerly “Defaulter”): a patient whose treatment was interrupted for 2 
months or more during the treatment period. 
Died: A patient who died for any reason during the course of TB treatment. 
Transfer out: A patient who started treatment and was transferred to another treatment unit 
and for whom the treatment outcome is not known at the time of evaluation of treatment 
results. 
Treatment success: The sum of patients who were declared ‘cured’ and those who had 
'completed’ treatment [2, 5, 36, 59]. 
Favourable/successful outcome: “Cured” and “completed”. 
Unfavourable/unsuccessful outcome: All outcomes that are not “successful” i.e., “failure” 
“died”, “defaulted” and “transferred out”.  
2.8 Administration ethical considerations  
Administrative authorisation was obtained from the director of the Laquintinie Hospital of 
Douala, Cameroon (appendix 1).  
Ethical approval was obtained from the Faculty of Health Sciences Institutional Review Board 
(FHS-IRB) - University of Buea, Cameroon (appendix 2). 
The Norwegian Ethical Committee in Bergen (REK) responded that ethical approval was not 




3.0 RESULTS   
In this study, patients that were newly diagnosed and who have never been treated before or 
have been treated for less than one month were classified as new cases while those who had a 
relapsed or returned after default were categorised as retreatment cases.  
3.1 Demographic characteristics  
This study recorded a total of 3615 TB patients registered at Laquintinie Hospital of Douala, 
Cameroon from 2016 to 2019. Amongst these, we analysed 3321 cases with complete treatment 
outcome data, in which 2887 (86.9%) were new cases and 434 (13.1%) were retreatment cases. 
There were more adults (between 25-54 years), fewer young (aged 0-14) and old patients (aged 
≥55 years) in both the new and retreatment groups. Males represented 53.9% of new and 58.1% 
of retreatment cases, shown in seen in Figure1.  
 
Figure 1: Age distribution of patients with tuberculosis at Laquintinie Hospital Douala, 
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Pulmonary TB (PTB) was recorded in 36.9% of the new cases and 51.4% in the retreatment 
cases; EPTB was recorded in 32.6% of the new cases and 17.5% of the retreatment cases, while 
30.5% of new cases and 31.1% of the retreatment cases presented both PTB and EPTB, Figure 
2.   
 
 
Figure 2: Disease site presentation amongst patients with tuberculosis at Laquintinie 
Hospital Douala, Cameroon from 2016 to 2019: new and retreatment cases  
 
The majority (67%) of the retreatment cases were recorded to have received standard regimen 
instead of the correct retreatment regimen. Furthermore, with respect to comorbidities, most 
patients had been tested for HIV, with 33.3% of new patients and 46.5% of retreatment cases 
being HIV positive. Out of those with a positive status, 715 (74.4%) of the new cases were on 
ARVs and 99.1% on Cotrimazole preventive treatment (CPT) whereas for the retreatment cases 
183 (90.6%) were on ARV and 97.5% on CPT as shown in table 3.1. 
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Table 3.1: Demographic and clinical characteristics of patients with TB at Laquintinie 
Hospital Douala, Cameroon from 2016 to 2019: new and retreatment cases  
 New cases Retreatment Cases 








Age group 0-14 247 8.6 12 2.8 
 15-24 435 15.1 37 8.5 
 25-34 750 26.0 98 22.6 
 35-44 608 21.1 134 30.9 
 45-54 409 14.2 93 21.4 
 55+ 438 15.2 60 13.8 
 Total 2887 100.0 434 100.0 
Gender Male 1557 53.9 252 58.1 
 Female 1329 46.0 182 41.9 
 Total 2886 100.0 434 100.0 
Year of diagnosis 2016 677 23.4 96 22.1 
 2017 673 23.3 92 21.2 
 2018 743 25.7 120 27.6 
 2019 794 27.5 126 29.0 
 Total  2887 100.0 434 100.0 
Disease site PTB 1066 36.9 223 51.4 
 Both PTB and EPTB 881 30.5 135 31.1 
 EPTB 940 32.6 76 17.5 
 Total 2887 100.0 434 100.0 
Drug regimen Standard1  2884 99.9 290 66.8 
 Retreatment2  3 0.1 144 33.2 
 Total 2887 100.0 434 100.0 
HIV status Negative 1883 65.2 227 52.3 
 Positive 961 33.3 202 46.5 
 Not recorded  43 1.5 5 1.2 
 Total 2887 100.0 434 100.0 
Eligible for ART services     
 Taking ARVs 715 74.4 183 90.6 
 Not taking ARVs 66 6.9 19 9.4 
 Not recorded 180 18.7 0 0 
 Total 961 100.0 202 100.0 
Eligible for CPT3     
 CPT given 952 99.1 197 97.5 
 CPT not recorded 9 0.9 5 2.5 
 Total 961 100.0 202 100.0 







3.2 Lab characteristic of TB patients in Laquintinie Hospital Douala, Cameroon 
from 2016 to 2019: new and retreatment cases 
A third of the patients who tested for smear microscopy were negative, and hence diagnosed on 
clinically. Gene Xpert was used in a 91(31%) of the new cases and 181(41.7%) of the 
retreatment cases. Failure, which is a positive smear result after treatment, was seen in 0.7% of 
all smear positive new cases. Among retreatment cases we found only one still positive after 
treatment, which gives a failure rate of 0.4%, table 3.2.   
Table 3.2: Laboratory results of patients with tuberculosis at Laquintinie Hospital 
Douala, Cameroon from 2016 to 2019  
 New cases Retreatment cases 
Variable  Frequency Percentage Frequency Percentage 
Initial smear results       
 Negative 506 32.3 84 27.6 
 + 518 33.1 114 37.5 
 ++ 530 33.8 104 34.2 
 +++ 13 0.8 2 0.7 
 Sub total 1567 100.0 304 100.0 
 Not recorded*** 1320 - 130 - 
 Total 2887  434  
GeneXpert1      
 MTB Not Detected 9 9.9 0 0.0 
 MTB Detected, R(+) 3 3.3 3 1.7 
 MTB Detected, R(-) 78 85.7 175 96.7 
 MTB Detected, R(?) 1 1.1 3 1.7 
 Sub total 91 100.0 181 100.0 
 Not recorded*** 2796 - 253 - 
 Total  2887  434  
Smear results after 5 months     
 Negative 917 98.8 104 99.2 
 + 11 1.2 2 1.9 
 Sub total 928 100.0 106 100.0 
 Not recorded*** 1959 - 249 - 
 Total 2887  434  
Smear results after Tx2     
 Negative 615 98.7 122 99.2 
 + 8 1.3 1 0.8 
 Sub total 623 100.0 123 100.0 
 Not recorded***  2264 - 311 - 
 Total 2887  434  
NB: Not recorded*** indicates not applicable for people with EPTB, not requested or missing                         





3.3 Description of treatment outcomes of registered tuberculosis patients at 
Laquintinie Hospital Douala, Cameroon from 2016 to 2019: new and retreatment 
Cases  
Six mutually exclusive outcomes were recorded after treatment of the TB patients: “cured”, 
“completed”, “failed”, “died”, “lost-to-follow-up”, or “transferred out”.  
In this study, patients who completed their treatment and/or were cured were considered to have 
as a successful treatment outcome, while those who had outcomes such as failure, died, 
defaulted, or transferred out were categorised as unsuccessful treatment outcome.  
Thus overall, new cases recorded a treatment success of 84.4% and retreatment cases 74.4%, 
table 3.3. Although in both the new and retreatment cases, the success rates seem to decrease 
from 2016-2019, new cases recorded a greater treatment success of at least 80% while 
retreatment cases had at least 68% from the period of 2016 to 2019, Figure 3 in the next page.  
 
Table 3.3: Treatment outcomes of patients with tuberculosis at Laquintinie Hospital 
Douala, Cameroon from 2016 to 2019  
Main category  Treatment 
Outcomes  
New Cases Retreatment Cases 
 Frequency (%) Frequency (%) 
Successful outcome  Cured 645 (22.3) 125 (28.8) 
Completed 1791 (62.0) 198 (45.6) 
Sub total  2436 (84.4) 323 (74.4) 
Unsuccessful outcome  Failure 16 (0.6) 6 (1.4) 
Died 153 (5.3) 30 (6.9) 
Defaulted 137 (4.8) 27 (6.2) 
Transfer out 145 (5.0) 48 (11.1) 
Sub total  451 (15.6) 111 (25.6) 








Figure 3: Successful and unsuccessful TB treatment outcomes of patients with tuberculosis 




Cross tabulations of treatment outcomes per baseline characteristics revealed that for the new 
cases, cured and completed combined (successful outcome) was above 80% in all age groups, 
and highest in the youngest (93%). Proportion deaths increased with age from 1.2% to 5%, lost 
to follow-up ranged from 2.4% to 5% in all age groups, and failures below 1% in all age groups, 
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Table 3.4: Treatment outcomes by baseline characteristics of patients registered with new 
tuberculosis at Laquintinie Hospital Douala - Cameroon, from 2016 to 2019 
 Frequency (%) 
 
Category  Total Cured Completed Failed Died Lost Transferred 
out 
Total    2887 (100.0) 645 (22.3) 1791 (62.0) 16 (0.6) 153 (5.3) 137 (4.7) 145 (5.0) 
Age        
 0-14 247 (100.0) 21 (8.5) 209 (84.6) 1 (0.4) 3 (1.2) 6 (2.4) 7 (2.8) 
 15-24 435 (100.0) 133 (30.6) 242 (55.6) 1 (0.2) 9 (2.1) 23 (5.3) 27 (6.2) 
 25-34 750 (100.0) 213 (28.4) 417 (55.6) 7 (0.9) 35 (4.7) 38 (5.1) 40 (5.3) 
 35-44 608 (100.0) 134 (22.0) 375 (61.7) 2 (0.3) 39 (6.4) 27 (4.4) 31 (5.1) 
 45-54 409 (100.0) 78 (19.1) 260 (63.6) 2 (0.5) 29 (7.1) 21 (5.1) 19 (4.6) 
 55+ 438 (100.0) 66 (15.1) 288 (65.8) 3 (0.7) 38 (8.7) 22 (5.0) 21 (4.8) 
 Total  2887 (100.0) 645 (22.3) 1781 (62.0) 16 (0.6) 153 (5.3) 137 (4.7) 145 (5.0) 
Gender        
 Male  1557 (100.0) 333 (21.4) 972 (62.4) 5 (0.3) 87 (5.6) 80 (5.1) 80 (5.1) 
 Female  1329 (100.0) 312 (23.5) 818 (61.6) 11 (0.8) 66 (5.0) 57 (4.3) 65 (4.9) 
 Total  2886 (100.0) 645 (22.3) 1790 (62.0) 16 (0.6) 153 (5.3) 137 (4.7) 145 (5.0) 
Year        
 2016 677 (100.0) 182 (26.9) 438 (64.7) 3 (0.4) 23 (3.4) 15 (2.2) 16 (2.4) 
 2017 673 (100.0) 109 (16.2) 436 (64.8) 2 (0.3) 40 (5.9) 70 (10.4) 16 (2.4) 
 2018 743 (100.0) 182 (24.5) 443 (59.6) 6 (0.8) 51 (6.9) 18 (2.4) 43 (5.8) 
 2019 794 (100.0) 172 (21.7) 474 (59.7) 5 (0.6) 39 (4.9) 34 (4.3) 70 (8.8) 
 Total  2887 (100.0) 645 (22.3) 1791 (62.0) 16 (0.6) 153 (5.3) 137 (4.7) 145 (5.0) 
Disease type        
 PTB 1947 (100.0) 637 (32.7) 947 (48.6) 13 (0.7) 122 (6.3) 111 (5.7) 117 (6.0) 
 EPTB 940 (100.0) 8 (0.9) 884 (89.8) 3 (0.3) 31 (3.3) 26 (2.8) 28 (3.0) 
 Total  2887 (100.0) 645 (22.3) 1791 (62.0) 16 (0.6) 152 (5.3) 137 (4.7) 145 (5.0) 
Drug regimen1        
 Standard1 2884 (100.0) 644 (22.3) 1789 (62.0) 16 (0.6) 153 (5.3) 137 (4.8) 145 (5.0) 
 Retreatment1  3 (100.0) 1 (33.3) 2 (66.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Total  2887 (100.0) 645 (22.3) 1791 (62.0) 16 (0.6) 152 (5.3) 137 (4.7) 145 (5.0) 
HIV status        
 Negative  1883 (100.0) 513 (27.2) 1125 (59.7) 8 (0.4) 58 (3.1) 87 (4.6) 92 (4.9) 
 Positive  961 (100.0) 128 (13.3) 633 (65.9) 8 (0.8) 94 (9.8) 48 (5.0) 50 (5.2) 
 Total  2844 (100.0) 641 (22.5) 1758 (61.8) 16 (0.6) 152 (5.3) 135 (4.7) 142 (5.0) 
HIV/ART Services        
 Not taking ARVs 66 (100.0) 8 (12.1) 36 (54.5) 0 (0.0) 11 (16.7) 1 (1.5) 10 (15.2) 
 Taking ARVs 715 (100.0) 97 (13.6) 483 (67.6) 5 (0.7) 64 (9.0) 34 (4.8) 32 (4.5) 
 Not Applicable  1882 (100.0) 513 (27.3) 1124 (59.7) 8 (0.4) 58 (3.1) 87 (4.6) 92 (4.9) 
 Total  2663 (100.0) 618 (23.2) 1643 (61.7) 13 (0.5) 133 (5.0) 122 (4.6) 134 (5.0) 




For the retreatment cases, approximately 74% success was recorded in all the age groups with 
the lowest (65%) recorded in the age group of 15-24 years. Unlike the new cases, more deaths 
were recorded, ranging from 4.1% to 6.8% in the various age groups. Also, 10.1% deaths were 
recorded among the HIV positives than their negative counterparts (3.1%). Lost-to-follow-up 





Table 3.5: Treatment outcomes by baseline characteristics of patients registered with 
tuberculosis for retreatment TB at Laquintinie Hospital Douala – Cameroon, from 2016 
to 2019 
  Frequency (%) 
 
Category  Total  Cured Completed Failed Died Lost Transferred 
out 
Total  434 (100.0) 125 (28.8) 198 (45.6) 6 (1.4) 30 (6.9) 27 (6.2) 48 (11.1) 
Age        
 0-14 12 (100.0) 2 (16.7) 7 (58.3) 0 (0.0) 1 (8.3) 0 (0.0) 2 (16.7) 
 15-24 37 (100.0) 11 (29.7) 13 (35.1) 1 (2.7) 3 (8.1) 2 (5.4) 7 (18.9) 
 25-34 98 (100.0) 25 (25.5) 42 (42.9) 1 (1.0) 4 (4.1) 7 (7.1) 19 (19.4) 
 35-44 134 (100.0) 42 (31.3) 63 (47.0) 1 (0.7) 8 (6.0) 7 (5.2) 13 (9.7) 
 45-54 93 (100.0) 29 (31.2) 42 (45.2) 2 (2.2) 10 (10.8) 6 (6.5) 4 (4.3) 
 55+ 60 (100.0) 16 (26.7) 31 (51.7) 1 (1.7) 4 (6.7) 5 (8.3) 3 (5.0) 
 Total  434 (100.0) 125 (28.8) 198 (45.6) 6 (1.4) 30 (6.9) 27 (6.2) 48 (11.1) 
Gender        
 Male  252 (100.0) 68 (27.0) 113 (44.8) 4 (1.6) 14 (5.6) 20 (7.9) 33 (13.1) 
 Female  182 (100.0) 57 (31.3) 85 (46.7) 2 (1.1) 16 (8.8) 7 (3.8) 15 (8.2) 
 Total  434 (100.0) 125 (28.8) 198 (45.6) 6 (1.4) 30 (6.9) 27 (6.2) 48 (11.1) 
Year        
 2016 96 (100.0) 35 (36.5) 46 (47.9) 0 (0.0) 7 (7.3) 2 (2.1) 6 (6.3) 
 2017 92 (100.0) 12 (13.0) 52 (56.5) 0 (0.0) 10 (10.9) 11 (12.0) 7 (7.6) 
 2018 120 (100.0) 46 (38.3) 46 (38.3) 4 (3.3) 7 (5.8) 3 (2.5) 14 (11.7) 
 2019 126 (100.0) 32 (25.4) 54 (42.9) 2 (1.6) 6 (4.8) 11 (8.7) 21 (16.7) 
 Total  434 (100.0) 125 (28.8) 198 (45.6) 6 (1.4) 30 (6.9) 27 (6.2) 48 (11.1) 
Disease type        
 PTB 358 (100.0) 123 (34.4) 140 (39.1) 6 (1.7) 27 (7.5) 23 (6.4) 39 (10.9) 
 EPTB 76 (100.0) 2 (2.6) 58 (76.3) 0 (0.0) 3 (3.9) 4 (5.3) 9 (11.8) 
 Total  434 (100.0) 125 (28.8) 198 (45.6) 6 (1.4) 30 (6.9) 27 (6.2) 48 (11.1) 
Drug regimen1         
 Standard1 290 (100.0) 90 (31.0) 130 (44.8) 4 (1.4) 15 (5.2) 20 (6.9) 31 (10.7) 
 Retreatment1  144 (100.0) 35 (24.3) 68 (47.2) 2 (1.4) 15 (10.4) 7 (4.9) 17 (11.8) 
 Total  434 (100.0) 125 (28.8) 198 (45.6) 6 (1.4) 30 (6.9) 27 (6.2) 28 (11.1) 
HIV status        
 Negative  227 (100.0) 79 (34.8) 91 (40.1) 4 (1.8) 7 (3.1) 17 (7.5) 29 (12.8) 
 Positive  202 (100.0) 46 (22.8) 105 (52.0) 2 (1.0) 22 (10.9) 9 (4.5) 18 (8.9) 
 Total  429 (100.0) 125 (29.1) 196 (45.7) 6 (1.4) 29 (6.8) 26 (6.1) 47 (11.0) 
HIV/ART services        
 Not taking ARVs 3 (100.0) 1 (33.3) 0 (0.0) 0 (0.0) 2 (66.7) 0 (0.0) 0 (0.0) 
 Taking ARVs 183 (100.0) 41 (22.4) 96 (52.5) 2 (1.1) 17 (9.3) 9 (4.9) 18 (9.8) 
 Not Applicable  226 (100.0) 79 (35.0) 90 (39.8) 4 (1.8) 7 (3.1) 17 (7.5) 29 (12.8) 
 Total  412 (100.0) 121 (29.4) 186 (45.1) 6 (1.5) 26 (6.3) 26 (6.3) 47 (11.4) 




3.4 Factors associated with unsuccessful treatment outcomes of patients with 
tuberculosis at Laquintinie Hospital Douala – Cameroon, from 2016 to 2019: new 
and retreatment cases 
 
3.4.1 New treatment cases 
Tables 3.6 provides detailed accounts of the results of the binary regression analysis (bivariate 
and multivariate analysis) of selected factors associated with unsuccessful TB treatment 
outcomes for the new cases.  
During the bivariate analysis, TB patients in the age group 0-14 years (OR 0.39, 95% CI: 0.23 
- 0.66), having extrapulmonary TB (OR 0.45, 95% CI: 0.35 – 0.58), and those for whom smear 
results were not applicable at diagnosis (OR 0.58, 95% CI: 0.42 - 0.80) had less risk of 
unsuccessful treatment outcome. However, being HIV positive (OR 1.76, 95% CI: 1.43 - 2.16), 
heavy smear (OR 1.69, 95% CI: 1.24 - 2.32), being diagnosed and having treatment in the years 
2017 (OR 2.56, 95% C.I: 1.83 - 3.56), 2018 (OR 2.05, 95% C.I: 1.47 – 2.87), 2019 (OR 2.49, 
95% C.I: 1.80 – 3.45) showed increased risk of unsuccessful outcome (table 5).  
In the multivariate analysis model, we adjusted for all the variables in the table: age, gender, 
year of diagnosis, disease type, HIV status and smear results before treatment. TB patients aged 
55years and above had about 50% increased risk of unsuccessful treatment outcomes (aOR 
1.53, 95% CI:  1.07 - 2.18) compared to those 25-34 years.  Furthermore, compared to HIV-
negatives, being HIV positive had more than double risk of unsuccessful treatment outcomes 
(aOR 2.26, 95% CI: 1.75 - 2.92). Patients with initial smear results (+) (aOR 1.57, 95% CI: 1.10 
- 2.22) and initial smear results (++) (aOR 2.01, 95% CI: 1.43 - 2.83) had higher risk of 
unsuccessful treatment outcome than those who has negative smear results.   The risk of 
unsuccessful treatment was almost double if being diagnosed and treated in 2017 (aOR 1.85, 
95% C.I: 1.25 – 2.73) and 2019 (aOR 2.13, 95% C.I: 1.48 – 3.06) compared to their counterparts 




Table 3.6: Association between unsuccessful treatment outcomes and selected 
determinants among new tuberculosis patients registered at Laquintinie Hospital Douala 
– Cameroon, 2016 to 2019 
Variable  Total Frequency (%) OR 95% C.I aOR 95% C.I 
  Success  Unsuccess      
Age  2887 2436 (84.4) 451 (15.6)     
 25-34 750 630 (84.0) 120 (16.0) -  -  
 0-14 247 230 (93.1) 17 (6.9) 0.39 0.23 - 0.66 0.66 0.35 - 1.22 
 15-24 435 375 (86.2) 60 (13.8) 0.84 0.60 - 1.18 0.94 0.65 - 1.37 
 35-44 608 509 (83.7) 99 (16.3) 1.02 0.76 - 1.37 0.91 0.65 - 1.26 
 45-55 409 338 (82.6) 71 (17.4) 1.10 0.80 - 1.52 1.06 0.74 - 1.52 
 55+ 438 354 (80.8) 84 (19.2) 1.25 0.92 - 1.70 1.53 1.07 - 2.18 
Gender 2886 2435 (84.4) 451 (15.6)     
 Male 1557 1305 (83.8) 252 (16.2) 1.10 0.89 - 1.34 1.17 0.93 - 1.48 
 Female 1329 1130 (85.0) 199 (15.0) -  -  
Year of diagnosis  2887 2436 (84.4) 451 (15.6)     
 2016 677 620 (91.6) 57 (8.4) -   -   
 2017 673 545 (81.0) 128 (19.0) 2.56 1.83 - 3.56 1.85 1.25 – 2.73 
 2018 743 625 (84.1) 118 (15.9) 2.05 1.47 – 2.87 1.47 0.99 – 2.17 
 2019 794 646 (81.4) 148 (18.6) 2.49 1.80 – 3.45 2.13 1.48 – 3.06 
Disease type  2887 2436 (84.4) 451 (15.6)       
 PTB 1947 1584 (81.4) 363 (18.6) -   -   
 EPTB 940 852 (90.6) 88 (9.4) 0.45 0.35 0.58 0.48 0.05 4.92 
HIV Status 2844 2399 (84.4) 445 (15.6)       
 Negative 1883 1638 (87.0) 245 (13.0) -  -  
 Positive 961 761 (79.2) 200 (20.8) 1.76 1.43 - 2.16 2.26 1.75 - 2.92 
Initial smear results 2493 2106 (84.5) 387 (15.5)       
 Negative 506 428 (84.6) 78 (15.4) -  -  
 Positive + 518 423 (81.7) 95 (18.3) 1.23 0.89 - 1.71 1.57 1.10 - 2.22 
 Positive ++ 530 405 (76.4) 125 (23.6) 1.69 1.24 - 2.32 2.01 1.43 - 2.83 
 Positive +++ 13 12 (92.3) 1 (7.7) 0.46 0.06 - 3.57 0.47 0.06 - 3.72 




3.4.2 Retreatment cases 
Table 3.7 shows the crude odds and adjusted odds of the selected factors associated with 
unsuccessful TB treatment outcomes for the retreatment cases.  
In the binary analysis, being diagnosed and receiving treatment in years 2017 (OR 2.26, 95% 
C.I: 1.16 – 4.79), 2019 (OR 2.51, 95% C.I: 1.29 – 4.89) showed increased risk of unsuccessful 
treatment outcome than those in 2016.  
In the multivariate analysis, we adjusted for age, gender, year of diagnosis, disease type, HIV 
status and smear results before treatment.  
The risk of unsuccessful treatment outcome was more than double among those diagnosed and 
treated in 2017 (aOR 0.53, 95%CI: 1.05 - 6.10), about three times in 2019 (aOR 2.93, 95% C.I: 
1.34 – 6.43) compared with those in 2016. However, the risk of unsuccessful treatment outcome 
was lower in the age groups of 35-44 years (aOR 0.50, 95% CI: 0.25 - 0.98), 55 years and above 






Table 3.7: Association between unsuccessful treatment outcomes and selected 
determinants among tuberculosis patients getting retreatment registered at Laquintinie 
Hospital Douala – Cameroon, 2016 to 2019 
Variable  Total Frequency (%) OR 95% C.I aOR  95% C.I 
  Success Unsuccess     
Age  434 323 (74.4) 111 (25.6)       
 25-34 98 67 (68.4) 31 (31.6) -   -   
 0-14 12 9 (75.0) 3 (25.0) 0.72 0.18 - 2.85 1.16 0.25 - 5.43 
 15-24 37 24 (64.9) 13 (35.1) 1.17 0.53 - 2.60 1.03 0.41 - 2.60 
 35-44 134 105 (78.4) 29 (21.6) 0.60 0.33 - 1.08 0.50 0.25 - 0.98 
 45-55 93 71 (76.3) 22 (23.7) 0.67 0.35 - 1.27 0.58 0.25 - 1.20 
 55+ 60 47 (78.3) 13 (21.7) 0.60 0.28 - 1.26 0.36 0.14 - 0.93 
Gender 434 323 (74.4) 111 (25.6)       
 Male 252 181 (71.8) 71 (28.2) 1.39 0.89 - 2.17 1.24 0.72 - 2.14 
 Female 182 142 (78.0) 40 (22.0) -      
Year of diagnosis  434 323 (74.4) 111 (25.6)       
 2016 96 81 (84.4) 15 (15.6) -  -  
 2017 92 64 (69.6) 28 (30.4) 2.36 1.16 – 4.79 2.53 1.05 – 6.10 
 2018 120 92 (76.7) 28 (23.3) 1.64 0.82 - 3.29 1.80 0.77 – 4.23 
 2019 126 86 (68.3) 40 (31.7) 2.51 1.29 – 4.89 2.93 1.34 – 6.43  
Disease type  434 323 (74.4) 111 (25.6)       
 PTB 358 263 (73.5) 95 (26.5) -   -   
 EPTB 76 60 (78.9) 16 (21.1) 0.74 0.41 - 1.34 0.58 0.02 - 18.02 
HIV Status 429 321 (74.8) 108 (25.2)       
 Negative 227 170 (74.9) 57 (25.1) -   -   
 Positive 202 151 (74.8) 51 (25.2) 1.01 0.65 - 1.56 1.21 0.69 - 2.14 
Initial smear results  377 287 (76.1) 90 (23.9)       
 Negative 84 67 (79.8) 17 (20.2) -   -   
 Positive + 114 83 (72.8) 31 (27.2) 1.47 0.75 - 2.89 1.74 0.85 - 3.57 
 Positive ++ 104 77 (74.0) 27 (26.0) 1.38 0.69 - 2.75 1.28 0.61 - 2.70 
 Positive +++ 2 2 (100) 0 (0) 0.00 0.00 0.00 0.00 







4.0 DISCUSSIONS, CONCLUSION AND RECOMMENDATIONS 
4.1 Discussion 
This study describes the treatment outcomes of registered TB patients, new and retreatment 
cases in Laquintinie Hospital of Douala, thus provides information on the epidemiology of TB 
in Douala, one of the main cities in Cameroon. TB was slightly more common in young adult 
males in both the new and retreatment groups. The HIV seropositivity rate was 33.3% and 
46.5% in the new and retreatment cases, respectively. The overall treatment success rates were 
84.4% in the new cases, and 74.4% in the retreatment cases. Aged 55 years and above, having 
HIV test positive, having initial smear results of (+) and (++), and being treated in 2017 and 
2019 were associated with a higher proportion of treatment unsuccess among the new cases. 
Poor treatment in the retreatment cases was determined by being diagnosed and treated in the 
years 2017 and 2019.  
4.1.1 Gender description of the study population  
Similar to other studies done in the same hospital in Douala [31], Ethiopia [55], India [60], 
Uzbekistan [61], Nepal [62] we observed a higher number of TB in males than females. Also 
the WHO reports that globally, more males being infected with TB than females (almost 2:1 
male to female ratio) [46]. However, studies in: Pakistan showed TB more in females than 
males; perhaps reason being the women have more restrictions to movements, and thus will 
commonly use the small diagnostic centres and health facilities that are closer to their houses 
where they can access by foot [63]; rural China where females visit lower local health facilities 
as compared to the men who rather seek health care in larger facilities [64]. The high proportion 
of TB in males in our study, could be due to social factors such as smoking and high alcohol 
consumption. In Cameroon, the proportion of males that consume alcohol is at least 1.5 times 
higher than that of females [65, 66], likewise a higher proportion of males (13.9%) who use 
tobacco products as compared to females (4.3%) [67]. Besides, other factor such as job-related 
risk could contributed to the high prevalence in males than females [46]. However, there seem 




4.1.2 Age description of the study population  
As reported in other studies [10, 69], we also observed a high proportion of TB among the 
adults. Unlike children around the age of 10years, adolescence and young adults turn to be more 
prone to TB disease from progression of latent infection. Also, the cumulative increasing 
prevalence of TB infection could also explain the common trend of higher incidence of TB 
disease with increase age [26, 70]. Thus as reported by the WHO, like in most African other 
states, it is likely that the TB infection in Cameroon is more prevalent amongst young adults 
than in high-income countries where the disease is predominantly among the elderly who may 
have been infected a long time ago and may get reactivations [46], or  among immigrants from 
high burden countries. The reduced risk of TB infections in high income countries during the 
last century has been due to improved health care/TB programs, improved economic, social 
status as compared to the low-income countries [31, 46]. 
4.1.3 TB type of the study population  
The EPTB of the new cases and of the retreatment is high. This could probably be due to the 
fact that it is a tertiary hospital which receives referral cases from other health care facilities 
[56] and maybe also a reflection of high HIV prevalence in the country. Three new TB cases 
got the retreatment drugs (2HREZS/1RHEZ/5RHE), rather than the standard treatment 
(2RHEZ/4RH) recommended by the NCTP and WHO [50], being treated for miliary TB. Also, 
66.8% of the retreatment cases got (2RHEZ/4RH). The facility did this for two reason – firstly, 
stock out of Streptomycin and secondly, they decided to commence with the modified treatment 
regimen for retreatment cases (3RHEZ/3RHEZ or 6RHEZ) as shown in table 1.2 which was to 
commence by 2020.  
4.1.4 TB smear results of the population  
In new cases, sputum microscopy found less than 1% strongly positive (+++), and almost a 
third each for (++), (+) and negatives. Tenue et al., [59], showed less than 1% (++++), and 
using a different category may explain the difference, as both showed around 1% in highest 
bacteria load. However, El-Sony et al., had among the 9.6% (514/5338) of the population who 
demonstrated acid fast bacilli 8.8% (+), 32.5% (++), and 58.8% (+++) [71]. Contrary to our 
study, this increase in percentage with grading could be because they worked with a population 
aged 15 – 49year old who could possibly produce good sputum.  
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4.1.5 HIV/AIDS status of the study population   
We noticed high rate of TB patients with known HIV status (98.5%). The percentage of TB 
patients of with documented HIV results in Cameroon stands 93% [50], 86% for the African 
region and 69% globally [46]. This high testing could be because all opt-out testing for HIV is 
done for all diagnosed TB patients and vice versa as recommended by the Centers for Disease 
Control and Prevention (CDC) and WHO [32]. Also, probably due to the scale-up of HIV 
testing to attain the 95-95-95 UNAIDS target, all people who come to the health facility are 
counselled and asked to do an HIV test by the physicians/psychosocial workers. One third of 
the new cases and almost one half of the retreatment cases tested positive to HIV on average. 
The co-infection rate in this study is quite high though similar to 37.6% gotten by [31] and 
35.6% gotten by [59] in Cameroon, 38% in San Francisco, US [54] and higher than 19% gotten 
by [72] in Thailand. Though the HIV prevalence of Cameroon (15 – 59years) has been declining 
over the past years, from 4.8% in 2002 to 4.1% in 2012 to 3.1% in 2019 [73],  the TB-HIV co-
infection status has not been good with Cameroon being ranked by the WHO among the top 41 
high TB-HIV burden countries in 2014 [74] to top 30 countries with high TB/HIV burden in 
the world and in the top 20 countries with the highest estimated number of incident TB cases 
among PLW HIV in 2019 [46].  
4.1.6 Successful treatment outcome   
The overall success rate success rate was (2436+323)/(2887+434) = 83.1% and is overall 
success rate obtained by Mbatchou et al., in a previous study at same hospital in was 75.2% 
[31]. This result is also better than success rates from other studies in Cameroon with 68.1% in 
Yaounde, [10], 78% in South West Region [59] and also other African studies, Ethiopia (60.1%) 
[75]; Nigeria (74%) [69], and Somalia (81.8%) [76]. The success rate of the new cases, 84.4% 
is closed to the target recommended by the WHO (85%) [46] and that of the Cameroon National 
TB Control Program (87%) [50] while that of the retreatment cases 74.4% is less.  The 
intensification of the community-based interventions programs and treatment done as spelled 
out by NCTB may have improved treatment success and, also reduce those lost-to-follow-up.  
Moreover, the collaboration between the MOH, and the CDC implementing partners in the 
domain of TB, HIV and the decentralization of diagnosis and treatment centres have possibly 
increased the awareness of the importance of treatment adherence, ensuring early HIV testing 
for those diagnosed with TB, proper DOTS follow-up might have also improved on the success 
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rate. However, other underlining factors such as poor living conditions, undernutrition, other 
comorbidities might have contributed to making the success rate below the expected value.   
Treatment completed was recorded as results in 62.0% and 45.6% in the new and retreatment 
group, respectively.  In both groups, the highest rates of treatment complete was recorded in 
the age groups 0 – 14 years while the lowest in 15-24 years. This could be because parents will 
want their children to get well, thus will do their best to ensure their kids take their medications 
to the end. Well as puberty sets in, there is slightly lower “compliance” with respect to taking 
the medications to the end especially when they start feeling well.  
4.1.7 Age, comorbidities, and treatment outcome   
The percentage of deaths increased progressively with increasing age especially in the new 
treatment group. Age related changes of the immune system can enhance susceptibility of the 
elderly to infectious diseases, failure of some vaccines, autoimmunity and also death [77].  
Moreover, this could be due to a variety of factors, including HIV and other comorbidities like 
diabetes. Haungu et al., in a systematic review showed very high association between patients 
with TB-diabetes mellitus and death [12]. Again, the case fatality among those positive for HIV 
in the new and retreatment groups was about three times to those HIV negative. Among the 
new cases, being HIV positive and not taking ART accounted for twice the number of deaths 
compared to those HIV positive and taking ARTs. A high association of mortality and HIV 
infection has been reported in many studies [10, 31, 54, 55, 69].  Those co-infected with 
HIV/TB are more likely to experience toxic reactions to drugs than those who are not HIV-
infected, increase pill burden since they will possibly have to take the HIV and TB drugs with 
the possible impact on adherence.  
4.1.8 Lost-to-follow-up  
An overall lost-to-follow-up of 4.9% was recorded. Several values of lost-to-follow-up have 
been reported: 4.2% in [78], 9.5% in [59], 20.1% in [10] in Cameroon; in several parts of the 
world: 2.9%, 3.4%, 16% and 17.4% in [79-82]. The differences noticed could be at the level of 
organization of the DOTS strategies adapted at the various settings. Like [59], more males were 
lost-to-follow-up than females in our study. The reason could be because women are more 
likely to follow and possibly adhere to treatment as compared to men in our settings [59] and 
in general [83]. Moreover, men are more mobile in this our settings for economic reasons. 
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4.1.9 Treatment failure   
Similar to [10, 59, 78], less than 2% failures were recorded in our study. Treatment failure after 
the standard treatment means the cases will have to be retreated. For those who failed after the 
retreatment, perhaps they did not adhere to the treatment or maybe multi drug resistant (MDR) 
TB has developed. This is not good for public health; thus, new investigations must be done 
including testing for MDR TB with GeneXpert and culture.    
4.1.10 Determinants of unsuccessful treatment outcome   
The determinants of unsuccessful treatment outcome in the new cases detected in multiple 
logistic regression analysis were: 55years and above, being HIV positive, patients with initial 
smear results of (+) / (++) and being diagnosed and treated in 2017. For the retreatment cases, 
the risk of unsuccessful treatment outcome was more than double among those diagnosed and 
treated in 2017 about three times in 2019. The reason for those aged 55 years above having 
increased risk of unsuccessful treatment outcomes could have been due to increased presence 
of comorbidities including diabetes [12].   
The year 2016 had a better treatment outcome as compared to all the other years as we move 
from 2017 to 2019. Year of diagnosis and treatment were strongly associated with treatment 
unsuccess with the years 2017 and 2019 having increases risk of treatment unsuccess.  One 
might one to think that the socio-political crisis in the country that began in 2017 (started as the 
strike of teachers of the English subsystem of education and common law lawyers) might have 
indirectly affected the management of the patients or influence the day-to-day activities, 
livelihood of the general population and TB patients, making them not to come for their drugs, 
being lost-to-follow-up, thus treatment unsuccess. There is an influx of internally displaced 
persons (from the South West and North West regions of Cameroon (the UN refugee agency 
reports 679,393 from those two regions by March 2020 [84]), into the other parts of the country 
including Douala due to the ongoing crisis in those mentioned regions. Some of these people 
might have TB, while others might be coming to live in the home of others that have or are 
currently being treated for TB. This may have led to poor follow-up of the TB patients by the 
limited health staff resulting to the declining treatment success across these years. Moreover, 
these people have to deal with other issues of their lives ranging from affected livelihood and 
economic activities, overcrowded housing, psychological stress, poor nutrition, which might 
have affected their treatment adherence and also their final outcome.  
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4.2 Strengths and limitations 
4.2.1 Strengths 
This study has several strengths. It uses data from routing setting and thus reflects the reality 
on the field - Douala, Littoral region of Cameroon. It uses standard categories of TB and can 
easily be compared with other studies. Double data entry was done to have quality assured data 
that was a truly a copy of the registers.  
4.2.2 Limitations  
There are some limitations to the study. This is routine TB registers, not research registers. 
Therefore, the data will contain some common errors and mistakes and omissions which may 
have affected the results.  
Secondly, variables not included in the registers are of course not available for analysis. Hence, 
many risk factors cannot be identified such as socio-economic status, household situation, 
alcohol consumption, social and behavioural factors.  
Thirdly, being a reference hospital, quite number of patients were transferred to a place closer 





4.3 Conclusion  
 
All in all, in this cohort, the success rate in the new cases was 84.4% and that of the retreatment 
cases 74.5%, below the target set by the National TB Control program and WHO. Overall 
success rate was higher than a previous study in the same area. Unsuccessful treatment was 
more common at the end of the study than the start, and HIV positive patients had a double risk 
of unsuccessful outcome. Around 10% of HIV positive TB patients died and only around 3% 
in HIV negatives. For new cases, unsuccessful treatment outcome was higher in patients aged 
>54years than those aged 25-34years, higher for patients with initial smear results of (+) and 
(++).  
 
4.4 Recommendations  
We therefore recommend the following: 
To researchers 
 Conduct further research to identify and evaluate socio-economic factors not captured 
in the TB registers which could be potential barriers to treatment success.   
 
For the National TB Control Program and ministry of public health (MoH) 
 To follow-up and ensure timely and proper documentation of lab results and other vital 
data not captured into the TB register. 
 Trace the lost-to-follow-up cases as they might still be positive and spreading the TB in 
the community.  
 Follow up of the failed retreatment cases to identify if drugs were not taken, testing for 
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